Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Female sexual dysfunction: potential for pharmacotherapy.

Jean L Fourcroy1

  • 1Uniformed Services University Health Sciences, Bethesda, Maryland 20817, USA. Fourcroy@aol.com

Drugs
|July 2, 2003
PubMed
Summary

Female sexual dysfunction (FSD) is complex, influenced by many factors. New drug development for FSD faces regulatory hurdles, focusing on orgasm over overall satisfaction, with several therapeutic paths under investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is elective vulvar plastic surgery ever warranted, and what screening should be conducted preoperatively?

The journal of sexual medicine·2007
Same author

Customs, culture, and tradition--what role do they play in a woman's sexuality?

The journal of sexual medicine·2006
Same author

Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women.

Antimicrobial agents and chemotherapy·2005
Same author

Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.

Pharmaceutical research·2005
Same author

A short course on the Food and Drug Administration: what you should know.

Journal of andrology·2002

Area of Science:

  • Reproductive Medicine
  • Pharmacology
  • Women's Health

Background:

  • Female sexual dysfunction (FSD) encompasses a range of disorders affecting desire, arousal, orgasm, and pain.
  • Diagnosis has evolved beyond the DSM-IV, incorporating psychogenic and organic causes.
  • The US FDA guidance emphasizes orgasm as a primary clinical trial endpoint for drug development.

Purpose of the Study:

  • To review current pharmaceutical approaches for treating female sexual disorders.
  • To examine the regulatory landscape for FSD drug development, particularly the FDA's focus on orgasm.
  • To discuss the potential of various therapeutic pathways and their safety/efficacy.

Main Methods:

  • Review of the literature on female sexual dysfunction classifications and treatments.
  • Analysis of US FDA guidance for clinical drug development.
  • Overview of current pharmaceutical research and development for FSD.

Main Results:

  • The FDA prioritizes orgasm as a trial endpoint, potentially overlooking broader female sexual satisfaction.
  • Six major pharmaceutical pathways are being explored: dopaminergic agonists, melanocortin-stimulating hormones, adrenoceptor antagonists, nitric oxide, prostaglandins, and androgens.
  • Numerous compounds targeting these pathways are in development for FSD.

Conclusions:

  • The development of effective and safe pharmacological treatments for FSD is ongoing.
  • There is a need to balance regulatory endpoints with the diverse aspects of female sexual satisfaction.
  • Future research will provide crucial data on the safety and efficacy of novel FSD therapeutics.

Related Experiment Videos